Within tumor-specific i.e. tetramer double positive CD8 T cells, we find that the majority were terminally differentiated (CD39+CD69+), which did not vary across TME checkpoint conditions (Figures 5E, F). The gene discussed is CD8A; the disease is neoplasm.